Drug intelligence / Profile preview

ciclosporin + infliximab + methotrexate + prednisolone

Development stage
Preclinical
Lead developer
Janssen Biotech
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration
Oral, Intravenous, Subcutaneous, Intramuscular
01

Overview

This is a combination therapy consisting of four immunosuppressive and anti-inflammatory agents used primarily for treating refractory rheumatoid arthritis. The combination includes ciclosporin (a calcineurin inhibitor), infliximab (a TNF-alpha inhibitor), methotrexate (a disease-modifying anti-rheumatic drug), and prednisolone (a corticosteroid). This combination may be used when patients cannot tolerate methotrexate alone or when disease activity remains high despite conventional therapy. Studies suggest that ciclosporin may be an alternative disease-modifying drug to be used in combination with infliximab in patients with refractory RA who cannot tolerate methotrexate.

02

Targets

TNFA (Tumor necrosis factor alpha (soluble))DHFR (Dihydrofolate reductase)GR (Glucocorticoid receptor)CN (Calcineurin)

Beyond the preview

Go deeper on ciclosporin + infliximab + methotrexate + prednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ciclosporin + infliximab + methotrexate + prednisolone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call